Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank92
3Y CAGR+8.4%
5Y CAGR+14.0%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+8.4%/yr
vs +51.0%/yr prior
5Y CAGR
+14.0%/yr
Recent deceleration
Acceleration
-42.6pp
Decelerating
Percentile
P92
Near historical high
vs 5Y Ago
1.9x
Solid growth
Streak
1 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $845.67M | +2.1% |
| 2024 | $828.62M | -3.1% |
| 2023 | $855.20M | +28.7% |
| 2022 | $664.40M | +11.2% |
| 2021 | $597.64M | +36.0% |
| 2020 | $439.32M | +52.9% |
| 2019 | $287.42M | +124.7% |
| 2018 | $127.92M | +152.0% |
| 2017 | $50.77M | +86.1% |
| 2016 | $27.28M | - |